Brought to you by 
Lilly buys CoLucid for $960mm; gets back its migraine candidate
08 Sep 2020
Executive Summary
Eli Lilly & Co. is paying $960mm ($46.50 per share in cash, a 36% premium) to acquire headache pain drug development firm CoLucid Pharmaceuticals Inc.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly buys CoLucid for $960mm; gets back its migraine candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice